BIO.B Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Bio-Rad Laboratories Inc (BIO.B) is not a strong buy at this time for a beginner investor with a long-term strategy. The technical indicators are neutral, financial performance shows significant declines in key metrics, and there are no recent positive news or strong catalysts to justify immediate investment. Analysts have lowered price targets, citing weak guidance and messy margins. While hedge funds are buying, the lack of strong trading signals and the current neutral sentiment suggest holding off on this stock for now.
The MACD is below 0 and negatively contracting, indicating a bearish trend. RSI is neutral at 49.434, and moving averages are converging, showing no clear direction. Key support is at 255.446, and resistance is at 290.086, with the stock currently trading near the pivot point of 272.766. Overall, the technical indicators suggest a neutral trend.
Hedge funds are significantly increasing their positions, with a 333305.80% increase in buying over the last quarter.
Analysts have lowered price targets, citing weak Q4 performance and messy margins. Financial performance shows a significant drop in net income (-200.59% YoY) and EPS (-204.22% YoY). No recent news or congress trading data to support a positive sentiment.
In Q4 2025, revenue increased by 3.85% YoY to $693.2M. However, net income dropped by -200.59% YoY to $720M, and EPS declined by -204.22% YoY to 26.65. Gross margin also fell by -2.89% YoY to 49.74%, indicating deteriorating profitability.
Analysts have lowered price targets: Wells Fargo reduced it to $320 from $340 with an Equal Weight rating, citing weak guidance. UBS lowered it to $335 from $350, maintaining a Buy rating but highlighting messy margins and headwinds. Overall, sentiment is mixed with a cautious outlook.
